Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma

Endocrine Journal

Volumn 63, Issue 10, 2016, Pages 905-912

  Okano, Yudai ^a   Satoh, Tetsurou ^a   Horiguchi, Kazuhiko ^a   Toyoda, Minoru ^a   Osaki, Aya ^a   Matsumoto, Shunichi ^a   Tomaru, Takuya ^a   Nakajima, Yasuyo ^a   Ishii, Sumiyasu ^a   Ozawa, Atsushi ^a   Shibusawa, Nobuyuki ^a   Shimada, Takehiro ^a   Higuchi, Tetsuya ^a   Chikamatsu, Kazuaki ^a   Yamada, Masanobu ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Hypophysitis; Malignant melanoma; Nivolumab; Secondary adrenal insufficiency; Treatment

Indexed keywords

ANTIBODY; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CREATININE; FLUORODEOXYGLUCOSE F 18; HYDROCORTISONE; LIOTHYRONINE; NITROGEN; NIVOLUMAB; PITUITARY CELL ANTIBODY 1; PRALMORELIN; PRASTERONE SULFATE; PROLACTIN; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG; UREA; VASOPRESSIN; MONOCLONAL ANTIBODY;

ADULT; ALCOHOL CONSUMPTION; ANTIBODY DETECTION; ARTICLE; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; ENDOSCOPY; EOSINOPHILIA; ESSENTIAL HYPERTENSION; FATIGUE; HISTOPATHOLOGY; HOSPITAL DISCHARGE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPONATREMIA; HYPOPHYSITIS; LABORATORY TEST; LIOTHYRONINE BLOOD LEVEL; LOSS OF APPETITE; MALE; MALNUTRITION; MEDICAL HISTORY; MELANOMA; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX TUMOR; PITUITARY FUNCTION TEST; PLASMA OSMOLARITY; POLYDIPSIA; POLYURIA; PRIMARY TUMOR; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; SMOKING; TESTOSTERONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT RESPONSE; TUMOR BIOPSY; UREA NITROGEN BLOOD LEVEL; VASOPRESSIN BLOOD LEVEL; CHEMICALLY INDUCED; DISEASE COURSE; OROPHARYNGEAL NEOPLASMS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; HUMANS; HYPOPHYSITIS; MALE; MELANOMA; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS;

EID: 84993971904     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ16-0161     Document Type: Article

References (25)

1. Caturegli P, Newschaffer C, Olivi A, Pomper MG, Burger PC, et al. (2005) Autoimmune hypophysitis. Endocr Rev 26: 599-614.
2. Umehara H, Okazaki K, Masaki Y, Kawano M, Yamamoto M, et al. (2012) A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details. Mod Rheumatol 22: 1-14.
3. Bando H, Iguchi G, Fukuoka H, Taniguchi M, Yamamoto M, et al. (2013) The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature. Eur J Endocrinol 170: 161-172.
4. Imura H, Nakao K, Shimatsu A, Ogawa Y, Sando T, et al. (1993) Lymphocytic infundibuloneurophysitis as a cause of central diabetes insipidus. N Engl J Med 329: 683-689.
5. Nishimura H, Honjo T (2001) PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol 22: 265-268.
6. Sharma P, Wagner K, WolchoK JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11: 805-812.
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancers. N Engl J Med 366: 2443-2454.
8. Torino F, Barnabei A, Paragliola RM, Marchetti P, Salvatori R, et al. (2013) mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol 169: R153-R164.
9. Torino F, Barnabei A, Paragliola R, Baldelli R, Appetecchia M, et al. (2013) Thyroid dysfunction as an unintended side effect of anticancer drugs. Thyroid 23: 1345-1366.
10. Corsello SM, Barnabei A, Marchetti P, Vecchis LD, Salvatori R, et al. (2013) Endocrine side effect induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 98: 1361-1375.
11. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, et al. (2014) Ipilimumab-induced hypophysitis: A detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99: 4078-4085.
12. Faje A (2016) Immunotherapy and hypophysitis. Pituitary 19: 82-92.
13. https://www.opdivo.jp/contents/clinical_trial/.
14. Kasperlik-Załuska AA, Czarnocka B, Czech W (2003) Autoimmunity as the most frequent cause of idiopathic secondary adrenal insufficiency: report of 111 cases. Autoimmunity 36: 155-159.
15. Caturegli P, Lupi I, Landek-Salgado M, Kimura H, Rose NR (2008) Pituitary autoimmunity: 30 years later. Autoimmun Rev 7: 631-637.
16. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
17. Teply BA, Lipson EJ (2014) Identification of management of toxicities from immune checkpoint-blocking drugs. Oncology (Williston Park) 28 Suppl 3: 30-38.
18. Ricciuti A, De Remigis A, Landek-Salgado MA, De Vincentiis L, Guaraldi F, et al. (2014) Detection of pituitary antibodies by immunofluorescence: Approach and results in patients with pituitary diseases. J Clin Endocrinol Metab 99: 1758-1766.
19. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, et al. (2014) Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 6: 230ra45.
20. Caturegli P, Iwama S (2013) From Japan with Love: Another tessera in the hypophysitis mosaic. J Clin Endocrinol Metab 98: 1865-1868.
21. Honegger J, Buchfelder M, Schlaffer S, Droste M, Werner S, et al. (2015) Treatment of primary hypophysitis in Germany. J Clin Endocrinol Metab 100: 3460-3469.
22. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, et al. (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13: 6681-6688.
23. Hinrichs, Palmer DC, Rosenberg SA, Restifo NP (2005) Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J Immunother 28: 517-524.
24. Marlier J, Cocquyt V, Brochez L, Van Bella S, Kruse V (2014) Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. Endocrine 47: 878-883.
25. Ishikawa M, Oashi K (2016) Case of hypophysitis caused by nivolumab. J Dermatol DOI 10.1111/1346-8138.13437.